theMednetRegister

Vasculitis   

Questions discussed in this category

How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
1 Answer available
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspi...
1 Answer available
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
2 Answers available
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
Would you view this as a sign that disease is not adequately controlled despite labs and imaging suggesting no active vasculitis? 
1 Answer available
How soon after starting treatment would you repeat imaging in patients with Takayasu to monitor response and ensure you have the correct diagnosis?
Do you monitor patients with CTAs or MRAs?
1 Answer available
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.
1 Answer available
What would be the preferred treatment option for PMR if patient develops gastric perforation soon after initiation of steroids?
1 Answer available
How would you approach management of nodular scleritis in the setting of suspected GCA?
Can nodular scleritis be a presenting manifestation of GCA?
1 Answer available
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
Would you be comfortable combining a TNFi with Rituxan in this patient? 
1 Answer available
How would you approach the workup and management of a young patient with recurrent biannual non-scarring oral ulcers and new onset neurologic symptoms with associated CNS white matter lesions concerning for Behcet’s?
1 Answer available
How would you manage a patient with ANCA associated vasculitis who has recurrent flare including pulmonary hemorrhage, persistent MPO antibody positivity while on maintenance rituximab and avacopan regimen even after induction rituximab therapy?
1 Answer available
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
Vasculitis involving aorta, subclavian, common carotid, SMA, IMA, renal artery, and celiac artery.
1 Answer available
How would you approach the workup and management of isolated inflammatory subglottic stenosis in a young previously healthy patient that is steroid responsive with a completely negative serologic autoimmune workup?
Would you push for biopsy before deciding on treatment?
1 Answer available
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
1 Answer available
How do you approach the work up of pulmonary artery aneurysm in the absence of other clinical features of Behcet’s?
1 Answer available
What features on CTA/MRA are most helpful for differentiating large vessel vasculitis from atherosclerosis?
1 Answer available
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
Patient is with past history of glomerulonephritis in remission after rituximab for the past 2 years. +MPO/P-ANCA
1 Answer available
How would you approach a pulmonary-renal PR3+ ANCA vasculitis patient who has persistent re-narrowing of mainstem bronchus after several dilatation and stenting procedures, with other anca features well-controlled on rituximab & avacopan?
5 Answers available
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
2 Answers available
Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?
2 Answers available
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
1 Answer available
Would you stop azathioprine in a patient with ANCA vasculitis who has been in long term remission on azathioprine, but has a new diagnosis of lung cancer requiring initiation of immunotherapy?
2 Answers available
When is brain biopsy useful/warranted as part of the diagnostic work-up in patients with suspected primary CNS angiitis?
3 Answers available
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
1 Answer available
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
2 Answers available
What is your approach to maintenance treatment in a patient with Sjogren's who received rituximab for mononeuritis multiplex?
And how would you monitor response?
1 Answer available
How would you approach the work up of a patient with nasal septal perforation, a negative infectious workup, and negative ANCA titers?
1 Answer available
Do you typically screen every patient with headaches after the age of 60 with ESR?
6 Answers available
How do you approach an older male with a chronic and persistent granulomatous cutaneous medium vessel vasculitis that has been unresponsive/worsened on high dose steroids, cyclophosphamide, and rituximab immunosuppressive agents with a thorough and unremarkable serologic, infectious, and imaging work-up?
2 Answers available
How would you approach a patient with new temporal headache, temporal artery tenderness and TA biopsy with mild thickening, but normal inflammatory markers?
1 Answer available
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
2 Answers available
What is your approach to further workup and treatment of abdominal aortitis found on imaging in asymptomatic individuals with elevated inflammatory markers?
Is there a role in temporal artery biopsy?
1 Answer available
How do you approach tapering immunosuppression in a patient with a history of Susac Syndrome who has stabilized on MMF and IVIG?
1 Answer available
How would you treat a young patient who presents with coronary vasculitis and aortitis with persistently positive MPO but no other features of AAV?
2 Answers available
How would you interpret a temporal artery biopsy demonstrating focal chronic inflammation in the adventitia associated with small adventitial vessels and nerves without inflammation of the intima and media and without giant cells?
2 Answers available
Would you continue Rituximab infusions in a patient with GPA and renal involvement who has been in remission on Avacopan and Rituximab, but had PRES post Rituximab infusion?
1 Answer available
How would you approach additional workup and management of a patient with active Crohn’s disease, who has multiple lung and brain nodules, with lung pathology demonstrating necrotizing granulomatous inflammation and brain biopsy with granulomatous inflammation and medium-large vessel vasculitis?
The patient is on mesalamine for Crohn’s and CellCept and HCQ for skin manifestations (currently on hold during workup). The infectious workup i...
1 Answer available
Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?
This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).
2 Answers available
Would you check ANCA titers in a patient with a history of PR-3-ANCA glomerulonephritis in remission and a stable creatinine but with recurrent microscopic hematuria?
6 Answers available
How would you approach peri-operative immunosuppressive management of a patient with Behcet's, currently controlled on azathioprine, who needs genital surgery?
The patient has not responded/has contraindications to apremilast, colchicine, and adalimumab. When they were off azathioprine for 5 days in the past,...
2 Answers available
Do you recommend monitoring IgG level in patients with AAV receiving rituximab?
And when do you consider (if ever) IGRT?
1 Answer available
Do you routinely obtain baseline vascular imaging (CTA, MRA, PET) in patients with suspected GCA, but negative temporal artery biopsy?
Per 2021 GCA Vasculitis Guidelines: low evidence, but conditional recommendation for CTA neck, chest, abd/pelvis. Is anybody following this or do you ...
2 Answers available
How would you approach management of incidentally identified unilateral retinal vasculitis with subsequent labs revealing +P-ANCA?
Patient is asymptomatic. Labs showed +P-ANCA 1:160. Negative MPO and PR3.
2 Answers available
What additional therapies would you consider in a pregnant woman with Bechet's on an antiTNF and azathioprine who has uncontrolled non-pulmonary large vessel vasculitis?
Vasculitis activity has been assessed with serial CTA of the chest and head/neck. She has existing right axillary artery disease and new areas of invo...
1 Answer available
How would you approach a patient with GCA who develops necrotizing fasciitis and then flares because they are off of tocilizumab?
How would you treat?  Would you view tocilizumab as an option in the future? 
1 Answer available
How do you approach deciding how long to use Avacopan for ANCA-associated vasculitis?
The ADVOCATE trial only studied use for 52 weeks. 
1 Answer available
How long do you continue immunosuppression in patients with Behcet's who have a history of mucocutaneous and ocular disease, but are now in remission?
1 Answer available
How would you approach a patient incidentally found to have PET avid large vessel vasculitis on CT angiogram during pre CABG workup?
Would you proceed with CABG procedure or treat the aortitis first?
1 Answer available
What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?
2 Answers available
How would you approach persistent episcleritis/uveitis due to PR3+ GPA, which needs low dose prednisone to control, despite induction with Rituximab?
Other manifestations improved (renal function has stabilized, fatigue, arthritis, and LCV have resolved). Ophthalmologist has controlled the uveitis u...
1 Answer available
Would you consider re-challenging a patient with rituximab after they experienced delayed neutropenia?
In a patient for whom rituximab is the best option for their disease management. 
2 Answers available
What is your approach for induction therapy in dual positive anti-GBM/PR3 disease with ESRD presenting with recurrent DAH previously treated with cyclophosphamide?
Is there a role of rituximab therapy over repeat cyclophosphamide? (Cyclophosphamide induction 2 years prior)
1 Answer available
Do you continue to utilize ESR and CRP in patients on tocilizumab?
2 Answers available
How would you taper tocilizumab in a patient treated with the GIACTA 26 week steroid and tocilizumab protocol?
When would you consider tapering? at one year? 18 months?
1 Answer available
How do you approach using CD 19/20 levels to redose Rituximab for ANCA associated vasculitis?
At what CD 19/20 level do you redose? Is this lab dependent?  Do you also use these levels to instruct patients when to get vaccinated?
2 Answers available
What is your approach to maintenance rituximab in patients with IgG4-RD?
1 Answer available
How would you approach a patient with incidentally noted infrarenal periaortitis with positive C-ANCA, normal inflammatory markers and no systemic symptoms?
MPO/PR3, P-ANCA negative. IgG4 normal.
1 Answer available
Do you routinely obtain a sural nerve biopsy in patients with EMG evidence of mononeuritis multiplex and clinically suspected polyarteritis nodosa?
1 Answer available
What is your approach to timing of medications like Rituximab and Cyclophosphamide around plasmapheresis in patients on daily PLEX?
4 Answers available
Do you routinely screen for pulmonary artery aneurysm in patients with Behcet's?
1 Answer available
Is IL-6 inhibition an option in patients who are going to be rechallenged with checkpoint inhibitors after previously developing ICI-mediated temporal arteritis?
Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?
2 Answers available
Do you recheck screening labs (ESR, BUN/Cr, urinalysis, ANA, etc) for patients with recurrent small vessel vasculitis of unknown origin with each flare?
1 Answer available
How do you approach treating idiopathic aortitis?
What are your primary and secondary agents?
1 Answer available
How would you treat localized cutaneous PAN recalcitrant to high-dose steroids?
1 Answer available
What is your approach to further workup, monitoring, and treatment of Sjogren's syndrome patients with positive cryoglobulins but no clear signs of vasculitis?
1 Answer available
How would you approach a rising PR3 in a patient with limited GPA who is currently asymptomatic on methotrexate?
Would you obtain imaging? If so, what type of imaging?
1 Answer available
What is your approach to treatment for patients with microscopic polyangiitis who have sustained remission at 6 months after induction rituximab?
Is there a role for monitoring for relapse or increased disease activity as opposed to scheduled dosing?
1 Answer available
How would you treat systemic polyarteritis nodosa with orchitis, mononeuritis and glomerulonephritis in a person who is being treated for HiV with low level viremia?
2 Answers available
How do you approach differentiating segmental arterial mediolysis from abdominal vasculitis?
1 Answer available
When do you consider tapering tocilizumab in patients with GCA in remission?
1 Answer available
What is your approach to the workup for an underlying systemic condition in a patient presenting with retinal vasculitis?
1 Answer available
How would you approach the treatment of checkpoint-inhibitor-mediated temporal arteritis?
Is there role for IVIG? Would you alter the dose or time course of steroid therapy?
2 Answers available
How important do you feel HLAB51 testing is in diagnosing Behcet's disease?
In your experience, are there specific disease manifestations in which HLAB51 is particularly helpful?
1 Answer available
Would you consider using avacopan in PR3+ mononeuritis multiplex without other systemic involvement?
1 Answer available
How do you approach relapsing ANCA-associated vasculitis in a patient who has already undergone kidney transplant?
1 Answer available
Can giant cell arteritis present with a partial cranial neuropathy?
3 Answers available
How do you approach treating cutaneous PAN?
Other than inflammatory markers and following symptoms/exam, do you need any other specific monitoring for progression to systemic disease? 
1 Answer available
Do you generally recommend low dose aspirin for patients with giant cell arteritis?
2 Answers available
Would you advise a patient with quiescent vasculitis who flared with the first Covid mRNA vaccine to obtain an additional dose?
Would you suggest switching to a viral vector vaccine, such as J&J?
2 Answers available
What is your approach to initial assessment of disease extent in patients with Behcet's disease?
How does this vary from continued disease monitoring?
1 Answer available
How would you approach new-onset large vessel vasculitis in a young patient with Crohn's disease?
3 Answers available
Do you always perform temporal artery biopsy in patients with positive inflammatory markers and high clinical suspicion of GCA?
2 Answers available
Is either ESR or CRP more sensitive or specific for the diagnosis of GCA?
Additionally, what is the current role for temporal artery ultrasound in workup for GCA?
3 Answers available
What is the utility in repeating a temporal ultrasound (US) in a previously US diagnosed positive GCA patient who has received treatment and is presenting with recurrent GCA symptoms?
1 Answer available
Is there any experience of using sarilumab instead of tocilizumab for steroid sparing effect in GCA during national tocilizumab shortage?
1 Answer available
What is the role for angiography in the workup of digital ischemia?
Do you obtain vascular imaging routinely in these cases, and if so, do you use cross-sectional or invasive angiography?
1 Answer available
What is your steroid-sparing agent of choice to treat GCA given the current tocilizumab shortage?
Thoughts on sarilumab vs methotrexate, or just treat with steroids alone
1 Answer available
What is your approach to checking serum vWF antigen levels in adult patients with CNS vasculitis for monitoring disease activity?
Small study in pediatric PACNS have evaluated this as a potential marker (Cellucci et al., PMID 22740622)
1 Answer available
Would you pursue temporal artery biopsy in patients with PMR who develop cranial GCA symptoms and have been on PMR dose steroids for one year?
1 Answer available
How long do you continue steroid-sparing agents such as tocilizumab for GCA once the disease is in remission off steroids?
1 Answer available
How do you approach treatment of vasculitis in a sickle cell disease patient?
There are multiple difficulties that could be seen: steroids can precipitate a sickle cell crisis, vasculitis and sickle cell can produce similar clin...
1 Answer available
What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?
1 Answer available
How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?
Would you change rituximab maintenance dose or schedule?
1 Answer available
How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?
1 Answer available
What is your approach for treating mononeuritis multiplex in patients with ANCA vasculitis?
Specifically, do you reach for Rituximab or cyclophosphamide?
1 Answer available
Would you start tocilizumab in a patient with temporal arteritis and cirrhosis?
1 Answer available
Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?
ADVOCATE trial
1 Answer available
How do you treat an AAV patient with recurrent bronchial stenosis that has not responded to rituximab induction therapy and dilatations?
1 Answer available
When would you use tocilizumab to treat Takayasu's?
1 Answer available
Are there features of a nerve biopsy that help distinguish late nerve damage from vasculitis versus from a demyelinating disease?
1 Answer available
How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?
In the ADVOCATE trial, patients were not re-dosed with rituximab.
1 Answer available
Are there particular subsets of AAV patients in which avacopan is more effective?
E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...
1 Answer available
Do you treat HIV/AIDS-associated CNS vasculitis with antiretrovirals alone or in combination with steroids?
1 Answer available
How do you monitor response to treatment in patients with mononeuritis multiplex secondary to vasculitis?
Given the slow recovery of nerve damage, what would you expect to see on a repeat EMG after treatment? Continued denervation or just sequelae of past ...
1 Answer available
How would you approach refractory gangrenous Raynaud's secondary to type one cryoglobulins?
What if the patient has MGUS? Do patients with type 1 cryoglobulins need a bone marrow biopsy as part of the work up?
1 Answer available
How would you approach a patient with MPO-positive isolated peripheral nerve vasculitis?
How would you label such a patient?  Would you treat differently if they have poor functional status?
2 Answers available
Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?
1 Answer available
Should all patients with suspected giant cell arteritis get a PET scan to look for large vessel disease?
3 Answers available
Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?
1 Answer available
What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 
1 Answer available
How do you approach a patient found to have a coronary lesion suggestive of vasculitis on coronary CT?
1 Answer available
Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?
1 Answer available
Should venous thrombosis in a patient with Behcet syndrome be treated with both immunosuppression and anticoagulation?
1 Answer available
How do you screen for colon cancer in patients with Behcet syndrome with colonic involvement?
1 Answer available
How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?
2 Answers available
At what point in GCA management do you typically introduce tocilizumab?
2 Answers available
Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?
2 Answers available
How do you manage incidentally identified chemotherapy-associated aortitis/large vessel vasculitis?
1 Answer available
How do you counsel Takayasu patients on their prognosis?
2 Answers available
Do you monitor RS3PE patients for GCA with the same vigilance that you do in PMR patients?
1 Answer available
How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?
1 Answer available
What agents can you use for treatment induction besides rituximab in cryoglobulinemic vasculitis (without hepatitis)?
1 Answer available
Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?
2 Answers available
When is a biopsy necessary to diagnose relapsing polychondritis?
1 Answer available
What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?
1 Answer available
What do you use to treat a GCA patient refractory to methotrexate who responded but had adverse effects with both tocilizumab and sarilumab?
1 Answer available
What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?
1 Answer available
Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?
 If you use both, how do you decide which to use for a particular patient?
2 Answers available
Is there a role for tocilizumab in treatment of polymyalgia rheumatica in patients who do not have features of giant cell arteritis or rheumatoid arthritis?
1 Answer available
When do you stop immunosuppressants in patients with GPA?
1 Answer available


Papers discussed in this category

N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Medicine (Baltimore),
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
The New England journal of medicine, 2010-07-15
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
,
Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.
Ann. Rheum. Dis., 2018 Apr 25
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Ann. Rheum. Dis., 2017 May 25
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Ann. Rheum. Dis., 2018 May 03
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Medicine, 1976-05
Relapsing polychondritis: prospective study of 23 patients and a review of the literature.
Arthritis and rheumatism, 2010-01
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
J. Rheumatol., 2019 Sep 01
Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.
Annals of the rheumatic diseases, 2009-03
EULAR recommendations for the management of primary small and medium vessel vasculitis.
BJR Case Rep, 2018 Sep 08
A case of aortitis during cisplatin-based chemotherapy for cervical cancer.
Ann Intern Med, 2020 Sep 22
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.
Curr Rheumatol Rep, 2020 Oct 16
Morbidity and Mortality of Large-Vessel Vasculitides.
N Engl J Med,
Trial of Tocilizumab in Giant-Cell Arteritis.
Lancet, 2016 Mar 04
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
JAMA network open, 2018-11-02
Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.
Rheumatol Int, 2020 Sep 18
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
The New England journal of medicine, 2017-05-18
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Kidney international reports, 2018-03
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
Rheumatology (Oxford),
A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
The Journal of rheumatology, 2012-02
Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis.
Rheumatology (Oxford, England), 2011-12
Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
Nat Rev Neurol,
The nonsystemic vasculitic neuropathies.
Nat Rev Dis Primers, 2018 Aug 02
Cryoglobulinaemia.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Rheumatology (Oxford),
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Ann Intern Med,
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
Ann Rheum Dis, 2011 Nov 29
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Annals of internal medicine, 1994-06-15
How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?
Front Neurol, 2019 Jun 06
Primary Angiitis of the Central Nervous System: New Potential Imaging Techniques and Biomarkers in Blood and Cerebrospinal Fluid.
Curr Opin Rheumatol,
Retinal vasculitis.
Arthritis Rheum,
Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
Seminars in arthritis and rheumatism, 2012-06
Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.
Arthritis Rheumatol, 2021 Jul 08
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.
Ann Rheum Dis, 2019 Jul 03
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Radiographics : a review publication of the Radiological Society of North America, Inc, 2001
Polyarteritis nodosa: spectrum of angiographic findings.
International journal of clinical rheumatology, 2010
Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management.
Mayo Clin Proc,
My Treatment Approach to Giant Cell Arteritis.
Neurology, 2019 Jan 11
RCVS score and diagnostic approach for reversible cerebral vasoconstriction syndrome.
Seminars in arthritis and rheumatism, 2016-02
Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature.
Bull Soc Ophtalmol Fr,
[Uveal effusion syndrome secondary to orbital cellulitis].
Am J Hum Genet, 2021 Jan 7
Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study.
Ann Rheum Dis, 2021 Jul 02
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis.
RMD Open, 2021 Sep
Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
J Dermatol,
Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases.
Arthritis Rheum,
Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
J Am Acad Dermatol, 2021 Jul 02
Efficacy and safety of treatments in cutaneous polyarteritis nodosa: A French observational retrospective study.
Arthritis Care Res (Hoboken), 2020 May 19
Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.
J Rheumatol, 2021 Feb 15
Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
Rheumatology (Oxford),
Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.
Eur J Cancer, 2021 Sep 15
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
Thorac Cancer, 2020 Feb 11
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).
The New England journal of medicine, 2013-08-01
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
N Engl J Med,
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
N Engl J Med,
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Rheumatol Int, 2014 Jun 05
Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.
Heart, 2021 Feb 16
Aortitis: recent advances, current concepts and future possibilities.
Arthritis Rheumatol, 2019 Nov 04
Outcomes Among 196 Patients With Noninfectious Proximal Aortitis.
Arthritis Rheumatol, 2022 Jun 20
Global Transcriptomic Profiling Identifies Differential Gene Expression Signatures Between Inflammatory and Noninflammatory Aortic Aneurysms.
Journal of vascular surgery, 2006-01
Takayasu's arteritis: operative results and influence of disease activity.
Rheumatology (Oxford), 2022 Jul 06
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
Clin Exp Rheumatol, 2022 Nov 02
Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.
Mayo Clinic proceedings, 2018-11
The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results.
Kidney Int, 2017 May 12
Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.
Arthritis Rheumatol, 2020 Sep 6
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
Rheumatology (Oxford, England), 2015-03
Large-vessel giant cell arteritis: a cohort study.
Annals of the rheumatic diseases, 2011 Sep 16
Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.
Open access rheumatology : research and reviews, 2016
Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.
Medicine, 2016 Feb
Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis.
Histopathology, 2023 Aug 08
Age-related histopathological findings in temporal arteries.
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology, 2023 Sep 06
Consensus statement on the processing, interpretation and reporting of temporal artery biopsy for arteritis.
Current opinion in rheumatology, 2018 Jul
Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.
European journal of medical research, 2009 Dec 07
Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.
Annals of the rheumatic diseases, 2018 Jun 27
Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
Annals of the rheumatic diseases, 2024 Jan 11
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012-08
Cyclophosphamide without corticosteroids for treatment of severe systemic necrotizing vasculitis.
Current medical research and opinion, 2016-12
Corticosteroids: the knee jerk response.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015-05
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
J Immunother Cancer, 2021 Jul
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016 Jul 07
Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Arthritis & rheumatology (Hoboken, N.J.), 2019 Oct 21
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
European journal of cancer (Oxford, England : 1990), 2023 Dec 28
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
Arthritis and rheumatism, 2006 Mar
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Annals of the rheumatic diseases, 2016 Jul 12
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
PloS one, 2014
IL-6 stimulates intestinal epithelial proliferation and repair after injury.
Current opinion in pulmonary medicine, 2023 Jun 30
Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment.
Rheumatology (Oxford, England), 2023 Feb 01
Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality.
JAMA otolaryngology-- head & neck surgery, 2020 Jan 01
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2024 Mar 14
Medical Maintenance Therapy Following Laser Excision in Patients With Granulomatosis With Polyangiitis (GPA)-Associated Subglottic Stenosis.
Antibiotics (Basel, Switzerland), 2023 May 29
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.
Clinical kidney journal, 2016 Nov 10
Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.
Expert review of anticancer therapy, 2009-01
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Lancet Gastroenterol Hepatol, 2023 Feb 01
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.